Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C33H46BN3O7 |
| Molecular Weight | 607.545 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)OCC3=CC=CC=C3)B4OC(C)(C)C(C)(C)O4
InChI
InChIKey=RTQCSXSGYPCGES-PKTNWEFCSA-N
InChI=1S/C33H46BN3O7/c1-32(2)33(3,4)44-34(43-32)28(19-13-21-41-5)36-29(38)27-18-12-20-37(27)30(39)26(22-24-14-8-6-9-15-24)35-31(40)42-23-25-16-10-7-11-17-25/h6-11,14-17,26-28H,12-13,18-23H2,1-5H3,(H,35,40)(H,36,38)/t26-,27+,28+/m1/s1
| Molecular Formula | C33H46BN3O7 |
| Molecular Weight | 607.545 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:03:29 GMT 2023
by
admin
on
Sat Dec 16 11:03:29 GMT 2023
|
| Record UNII |
DUP7T3BT69
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
162854-81-1
Created by
admin on Sat Dec 16 11:03:29 GMT 2023 , Edited by admin on Sat Dec 16 11:03:29 GMT 2023
|
PRIMARY | |||
|
11599726
Created by
admin on Sat Dec 16 11:03:29 GMT 2023 , Edited by admin on Sat Dec 16 11:03:29 GMT 2023
|
PRIMARY | |||
|
DUP7T3BT69
Created by
admin on Sat Dec 16 11:03:29 GMT 2023 , Edited by admin on Sat Dec 16 11:03:29 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Bioavailability is the fraction or percentage of a dose that reaches the systemic circulation intact, as compared to an intravenous injection. When administered at a doses of 20 mg/kg, TRI 50b was found to have bioavailabilities of 10.3%, 13.2% and 41.0% from formulations 1, 2 and 3, respectively, calculated as the AUC (area under the curve) for the oral formulation as a percentage of the AUC following direct injection. Thus, formulation 3, which contained the saturated polyglycolized glyceride (Gelucire), was found to produce a dramatic and surprising increase in the measured bioavailability of the lipophilic thrombin inhibitor TRI 50b.
|
||
|
ACTIVE MOIETY |
Class: Anticoagulant, Antithrombotic; Mechanism of Action: Thrombin inhibitor; Highest Development Phase: Discontinued for Thrombosis; Most Recent Events: 22 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Hematology (ASH-2003) have been added to the pharmacokinetics and Thrombosis pharmacodynamics sections, 18 Nov 2003 Discontinued - Clinical-Phase-Unknown for Thrombosis in Poland (IV)
|
